Immune to Cancer: The CRI Blog
-
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.
-
Cancer Research Institute Raises $1.2 Million at Annual Through the Kitchen
On Sunday, May 16, 2016, the Cancer Research Institute (CRI) held its 34th annual “Through the Kitchen”…
-
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.
-
Questions About Cancer Immunotherapy? Ask a Scientist!
We’re excited to present our newest educational initiative for patients—the Ask a Scientist video series.
-
#AACR16 Update: Vice President Biden and the National Cancer Moonshot Initiative
VP Biden addresses AACR16 seeking suggestions and solutions.
-
#AACR16 Update: The Promise of Synthetic Biology and CAR T Cell Technologies
Genetically engineered cells can be customized to target cancer.
-
#AACR16 Update: New Hope for Patients with Rare Skin Cancer, Head & Neck Cancer
Anti-PD-1 blockade and two other types of immunotherapy effective in treating multiple tumor types.
-
#AACR16 Update: The Cancer Research Institute’s Impact on Immunotherapy
Since our founding in 1953, the Cancer Research Institute has pioneered the field of cancer immunology, and… -
#AACR16 Update: How Immune Infiltration Predicts Survival in Cancer Patients
The Immunoscore is the strongest prognostic marker in colorectal cancer.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.